NCT02646358View on ClinicalTrials.gov

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 30, 2016

Conditions
Pharmacokinetics of VepoloxamerHealthy VolunteersRenal Impaired
Interventions
DRUG

Vepoloxamer

Trial Locations (2)

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

Sponsors
All Listed Sponsors
lead

Mast Therapeutics, Inc.

INDUSTRY

NCT02646358 - Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer | Biotech Hunter | Biotech Hunter